uniQure N.V. - 8-K Filing
On June 19, 2026, uniQure N.V. announced preliminary data from the first cohort in its Phase I/IIa clinical trial of AMT-260 for refractory mesial temporal lobe epilepsy (MTLE). Three out of six patients in the low-dose cohort experienced seizure reductions ranging from 79% to 100%, while others showed variable changes. No serious adverse events were reported, with all side effects classified as mild or moderate. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $QURE